Kieran Adam

536 total citations
26 papers, 350 citations indexed

About

Kieran Adam is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kieran Adam has authored 26 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 15 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Kieran Adam's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Immune Cell Function and Interaction (8 papers). Kieran Adam is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Immune Cell Function and Interaction (8 papers). Kieran Adam collaborates with scholars based in United States, Greece and Israel. Kieran Adam's co-authors include Anna S. Tocheva, Adam Mor, Adam Mor, Marianne Strazza, Michael Peled, Alina C. Iuga, Shalom Lerrer, Ian M. Ahearn, Antonio García‐España and Xiang‐Peng Kong and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Kieran Adam

24 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kieran Adam United States 11 195 191 73 37 24 26 350
D. Tibaudi Italy 5 235 1.2× 148 0.8× 116 1.6× 46 1.2× 25 1.0× 7 424
Alessandra Jales United States 6 137 0.7× 144 0.8× 118 1.6× 42 1.1× 20 0.8× 6 329
Katherine A. Waugh United States 7 215 1.1× 248 1.3× 68 0.9× 49 1.3× 13 0.5× 16 423
Pilar Nava-Parada United States 9 90 0.5× 131 0.7× 100 1.4× 23 0.6× 27 1.1× 14 286
Jianquan Hou China 7 124 0.6× 175 0.9× 67 0.9× 35 0.9× 14 0.6× 15 311
Agnieszka Karczmarczyk Poland 8 76 0.4× 189 1.0× 81 1.1× 22 0.6× 18 0.8× 24 341
Fernanda Pilataxi United States 8 195 1.0× 199 1.0× 46 0.6× 104 2.8× 8 0.3× 15 383
Grégoire Berthod Switzerland 10 298 1.5× 123 0.6× 119 1.6× 95 2.6× 41 1.7× 24 433
Leting Zheng China 9 108 0.6× 142 0.7× 98 1.3× 40 1.1× 16 0.7× 18 317
Kana Miyazaki Japan 12 228 1.2× 86 0.5× 50 0.7× 17 0.5× 17 0.7× 46 403

Countries citing papers authored by Kieran Adam

Since Specialization
Citations

This map shows the geographic impact of Kieran Adam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kieran Adam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kieran Adam more than expected).

Fields of papers citing papers by Kieran Adam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kieran Adam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kieran Adam. The network helps show where Kieran Adam may publish in the future.

Co-authorship network of co-authors of Kieran Adam

This figure shows the co-authorship network connecting the top 25 collaborators of Kieran Adam. A scholar is included among the top collaborators of Kieran Adam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kieran Adam. Kieran Adam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wai, Christine, Kieran Adam, Edward Moreira Bahnson, et al.. (2025). Uremic serum exposure leads to differential phenotypic switch in porcine arterial and venous smooth muscle cells. American Journal of Physiology-Renal Physiology. 329(6). F809–F819.
2.
Bukhari, Shoiab, Kieran Adam, Shalom Lerrer, et al.. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer. 12(3). e008482–e008482. 4 indexed citations
3.
Adam, Kieran, Zhanna Lipatova, Maria Abdul Ghafoor Raja, et al.. (2024). Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity. The Journal of Immunology. 213(1). 7–13. 9 indexed citations
4.
Adam, Kieran, et al.. (2024). Advances in LAG3 cancer immunotherapeutics. Trends in cancer. 11(1). 37–48. 10 indexed citations
5.
Gartshteyn, Yevgeniya, Anca Askanase, Ruijiang Song, et al.. (2022). SLAMF6 compartmentalization enhances T cell functions. Life Science Alliance. 6(2). e202201533–e202201533. 11 indexed citations
6.
Strazza, Marianne, et al.. (2022). Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth. Molecular Therapy — Methods & Clinical Development. 27. 380–390. 4 indexed citations
7.
Bukhari, Shoiab, Brian S. Henick, Robert Winchester, et al.. (2022). Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Reports Medicine. 4(1). 100868–100868. 41 indexed citations
8.
Strazza, Marianne, Inbar Azoulay‐Alfaguter, Michael Peled, Kieran Adam, & Adam Mor. (2021). Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells. Communications Biology. 4(1). 672–672. 13 indexed citations
9.
Lerrer, Shalom, Anna S. Tocheva, Shoiab Bukhari, Kieran Adam, & Adam Mor. (2021). PD-1-stimulated T cell subsets are transcriptionally and functionally distinct. iScience. 24(9). 103020–103020. 11 indexed citations
10.
Adam, Kieran, Alina C. Iuga, Anna S. Tocheva, & Adam Mor. (2021). A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS ONE. 16(2). e0246168–e0246168. 45 indexed citations
11.
Strazza, Marianne, Kieran Adam, Shalom Lerrer, et al.. (2021). SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function. Inflammation. 44(4). 1529–1539. 15 indexed citations
12.
Peled, Michael, Anna S. Tocheva, Kieran Adam, & Adam Mor. (2021). VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses. Immunology Letters. 233. 42–47. 6 indexed citations
13.
Peled, Michael, Kieran Adam, & Adam Mor. (2021). Data on the identification of VRK2 as a mediator of PD-1 function. SHILAP Revista de lepidopterología. 37. 107168–107168.
14.
Tocheva, Anna S., Michael Peled, Marianne Strazza, et al.. (2020). Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. Journal of Biological Chemistry. 295(52). 18036–18050. 21 indexed citations
15.
García‐España, Antonio, Anna S. Tocheva, Ian M. Ahearn, et al.. (2019). The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. Journal of Biological Chemistry. 295(14). 4372–4380. 67 indexed citations
16.
Adam, Kieran, et al.. (2005). HLA antigens in Greek children with allergic bronchial asthma. Tissue Antigens. 65(5). 481–484. 15 indexed citations
17.
Adam, Kieran, et al.. (2001). Can HLA Typing Predict the Outcome of Grass Pollen Immunotherapy?. PubMed. 18(1). 13–23. 5 indexed citations
18.
Pratsidou‐Gertsi, Polyxeni, Anastasios E. Germenis, Kieran Adam, et al.. (1999). Nationwide collaborative study of HLA class II associations with distinct types of juvenile chronic arthritis (JCA) in Greece. European Journal of Immunogenetics. 26(4). 299–310. 23 indexed citations
19.
Adam, Kieran, et al.. (1994). HLA class II DNA-RFLP typing in 102 individuals from Northern Greece. Transplant International. 7(s1). 522–526. 2 indexed citations
20.
Adam, Kieran, et al.. (1992). HLA-A, B, DR antigens and renal transplantation from cadaveric donors and living-related donors in Greek patients.. PubMed. 24(6). 2449–50. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Tibaudi Breakdown of academic impact, for papers by Alessandra Jales Breakdown of academic impact, for papers by Katherine A. Waugh Breakdown of academic impact, for papers by Pilar Nava-Parada Breakdown of academic impact, for papers by Jianquan Hou Breakdown of academic impact, for papers by Agnieszka Karczmarczyk Breakdown of academic impact, for papers by Fernanda Pilataxi Breakdown of academic impact, for papers by Grégoire Berthod Breakdown of academic impact, for papers by Leting Zheng Breakdown of academic impact, for papers by Kana Miyazaki
Rankless by CCL
2026